MAHZI THERAPEUTICS

Mahzi Therapeutics, a recently launched biotech company,

is focused on new therapies for CHD2 and other other neurodevelopmental disorders.

 

Mahzi, in collaboration with the Ulitsky lab at the Weizmann Institute of Science, Rehovot, is developing an ASO approach for the treatment of CHD2 deficiency.

www.mahzi.com

Capture.JPG